Clinical evaluation of response to long-term treatment with Pranlukast in patients with bronchial asthma

Journal of Investigational Allergology and Clinical Immunology

Volumn 14, Issue 4, 2004, Pages 284-291

  Niitsuma, Tomoyuki ^a   Izawa, J ^a   Maruoka, N ^a   Nukaga, M ^a   Tsuji, A ^a   Okita, M ^a   Sakurai, K ^a   Morita, S ^a   Tsuyuguchi, M ^a   Matsumura, Y ^a   Hayashi, T ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Bronchial asthma; Leukotriene receptor antagonist; Pranlukast

Indexed keywords

ANTIINFLAMMATORY AGENT; BECLOMETASONE DIPROPIONATE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FENOTEROL; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; PRANLUKAST; PREDNISOLONE; PROCATEROL; THEOPHYLLINE;

ADULT; AGED; ARTICLE; ASTHMA; CHRONIC DRUG ADMINISTRATION; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FOLLOW UP; HUMAN; LONG TERM CARE; MALE; OUTCOMES RESEARCH; PEAK EXPIRATORY FLOW; RETROSPECTIVE STUDY; SIDE EFFECT; STATISTICAL ANALYSIS; SYMPTOM;

ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; CHROMONES; CIRCADIAN RHYTHM; FEMALE; HUMANS; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE;

EID: 20144364351     PISSN: 10189068     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Obata, T., Katsube, N., Miyamoto, T., Toda M., Okegawa, T., Nakai, H., Kosuge S., Konno M., Arai, Y., Kawasaki, A. New antagonists of leukotrienes: ONO-RS-411 and ONO-RS-347. Adv Prostaglandin Thromboxane Leukot Res. 1985, 15:229-31.
2. Adaikan, PG., Lau, LC., Kottegoda, SR., Ratnam, SS. Effects of two new leukotriene antagonists ONO-RS-347 and ONO-RS-411 (ONO-1078) on the guinea pig and human respiratory and other systems. Adv Prostaglandin Thromboxane Leukot Res. 1987, 17, 549-53.
3. Miyamoto, T., Takishima, S., Tamura, G., Yasui, S., Takahashi, K., Takada, K., Kasukawa, R., Ohhara, M., Kobayashi, S., Kurosawa, M., Makino, S., Motojima, S., Sukou, M., Mano, K., Urata, C., Kabe, J., Kudo, K., Takahashi, T., Adachi, M., Sano, Y., Miyamoto Y., Shida, T., Watanabe K., Nagaoka, S., Mikami, M., Miyaji, S., Nakazawa, H. Utility of leukotriens C4, D4, and E4 antagonist ONO-1078, on adult bronchial asthma in multicenter comparative double-blind clinical study with azelastine hydrochloride. Rinshou Igaku 1993, 9(suppl.1), 31-52.
4. Barnes, NC., Pujet, JC. Pranlukast, a novel leukotriene receptor antagonist: results of the first European, placebo controlled, multicentre clinical study in asthma. Thorax 1997, 52, 523-7.
5. Grossman, J., Faiferman, I., Dubb, JW., Tompson, DJ., Busse, W., Bronsky ,E., Montanaro, A., Southern, L., Tinkelman, D. Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. J Asthma 1997, 34, 321-8.
6. Yoo, SH., Park, SH., Song, JS., Kan, KH., Park, CS., Yoo, JH., Choi, BW., Hahn, MH. Clinical effects of pranlukast, an oral leukotriene receptor antagonist, in mild-to-moderate asthma, a 4 week randomized multicentre controlled trial. Respirology 2001, 6, 15-21.
7. Yoshida, S., Ishizaki, Y., Shoji, T., Onuma, K., Nakagawa, H., Nakabayashi, M., Akahori, K., Hasegawa, H., Amayasu, H. ffect of pranlukast on bronchial inflammation in patients with asthma. Clin Exp Allergy. 2000, 30, 1008-14.
8. Tamaoki, J., Kondo, M., Sakai, N., Nakata, J., Takemura, H., Nagai, A., Takizawa, T., Konno K. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. Am J Respir Crit Care Med. 1997, 155, 1235-40.
9. Tomari, S., Shimoda, T., Kawano, T., Matsuse, H., Kohno, S. Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma. Ann Allergy Asthma Immunol. 2001, 87, 156-61.
10. Kohrogi, H., Iwagoe, H., Fujii, K., Hamamoto, J., Fukuda, K., Hirata, N., Kawano, O., Matsumoto, M., Suga, M., Ando, M. The role of cysteinyl leukotrienes in the pathogenesis of asthma: clinical study of leukotriene antagonist pranlukast for 1 year in moderate and severe asthma. Respirology 1999, 4, 319-23.
11. Makino, S., Hurusho, M., Miyamoto, T. (ed.) The Guidelines for Prevention and Management of Asthma. Kyowa Kikaku Tsushin, Tokyo, 1998, 65-183.
12. Robinson, C., Holgate, ST. Mast cell-dependent inflammatory mediators and their putative role in bronchial asthma. Clin. Sci. 1985, 68, 103-12.
13. O'Byrne, PM. Leukotrienes, airway hyperresponsiveness, and asthma. Ann N Y Acad Sci. 1988, 524, 282-8.
14. Jonathan, P., Lee, TH. Leukotrienes and bronchial hyperresponsiveness. Acta Paediatr Jpn. 1987, 29, 645-648
15. Marom, Z., Shelhamer, JH., Bach, MK., Morton DR., Kaliner M. Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. Am Rev Respir Dis. 1982, 126, 449-51.
16. Peck, MJ., Piper, PJ., Williams, TJ. The effect of leukotrienes C4 and D4 on the microvasculature of guinea-pig skin. Prostaglandins 1981, 2, 315-21.
17. Rinkema, LE., Bemis, KG., Fleisch, JH. Production and antagonism of cutaneous vascular permeability in the guinea pig in response to histamine, leukotrienes and A23187. J Pharmacol Exp Ther. 1984, 230, 550-7.
18. Laitinen, LA., Laitinen, A., Haahtela, T., Vilkka, V., Spur, BW., Lee, TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet 1993, 341, 989-90.
19. Hamilton, A., Faiferman, I., Stober, P., Watson, RM., O'Byrne, PM. Pranlukast, a cysteinyl leukotriene receptor antagonist, attenuates allergen-induced early- and late-phase bronchoconstriction and airway hyperresponsiveness in asthmatic subjects. J Allergy Clin Immunol. 1998, 102, 177-83.
20. Fujimura, M., Sakamoto, S., Kamio, Y., Matsuse, T. Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma. Respir Med. 1993, 87, 133-8.
21. Tanaka, H., Saito, T., Kurokawa, K., Teramoto, S., Miyazaki, N., Kaneko, S., Hashimoto, M., Abe, S. Leukotriene (LT)-receptor antagonist is more effective in asthmatic patients with a low baseline ratio of urinary LTE4 to 2,3-dinor-6-keto-prostaglandin (PG) F1 alpha. Allergy 1999, 54, 489-94.